The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Abstract
Context: Berberine, a natural plant alkaloid, is usually used as an antibiotic drug. The potential glucose-lowering effect of berberine was noted when it was used for diarrhea in diabetic patients. In vitro and in vivo studies have then showed its effects on hyperglycemia and dyslipidemia. Objective: The objective of the study was to evaluate the efficacy and safety of berberine in the treatment of type 2 diabetic patients with dyslipidemia. Design: One hundred sixteen patients with type 2 diabetes and dyslipidemia were randomly allocated to receive berberine (1.0 g daily) and the placebo for 3 months. The primary outcomes were changes in plasma glucose and serum lipid concentrations. Glucose disposal rate (GDR) was measured using a hyperinsulinemic euglycemic clamp to assess insulin sensitivity. Results: In the berberine group, fasting and postload plasma glucose decreased from 7.0 ± 0.8 to 5.6 ± 0.9 and from 12.0 ± 2.7 to 8.9 ± 2.8 mm/liter, HbA1c from 7.5 ± 1.0% to 6.6 ± 0.7%, triglyceride from 2.51 ± 2.04 to 1.61 ± 1.10 mm/liter, total cholesterol from 5.31 ± 0.98 to 4.35 ± 0.96 mm/liter, and low-density lipoprotein-cholesterol from 3.23 ± 0.81 to 2.55 ± 0.77 mm/liter, with all parameters differing from placebo significantly (P < 0.0001, P < 0.0001, P < 0.0001, P = 0.001, P < 0.0001, and P <0.0001, respectively). The glucose disposal rate was increased after berberine treatment (P = 0.037), although no significant change was found between berberine and placebo groups (P = 0.063). Mild to moderate constipation was observed in five participants in the berberine group. Conclusions: Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two cases of liver function abnormalities were reported in one study in the berberine group,(29) although two studies reported no increase or a decrease in liver transaminases with berberine.(32, 34)”
From Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials (2022) · cites this paper as [32]
In the citing paper
“Further analysis suggested that this was likely due to most participants in this subgroup having normal blood glucose levels, as berberine does not significantly affect normal values for these indicators (Zhang et al., 2008; An et al., 2014; Wang et al., 2016b).”
From Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials (2025) · cites this paper as Zhang et al., 2008
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Ford, E. S. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1769 · Cited by 1,718
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Lee, Y. S., Kim, W. S., Kim, K. H., Yoon, M. J., Cho, H. J., Shen, Y., Ye, J.-M., Lee, C. H., Oh, W. K., Kim, C. T., et al. (2006) · Diabetes · doi:10.2337/db06-0006 · Cited by 1,054
Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1108 · Cited by 568
Berberine improves glucose metabolism through induction of glycolysis
Yin, J., Gao, Z., Liu, D., Liu, Z., & Ye, J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00211.2007 · Cited by 418
Zuo, F., Nakamura, N., Akao, T., & Hattori, M. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011361 · Cited by 284
Leng, S.-H., Lu, F., & Xu, L. (2004) · PubMed · Cited by 237
Research works printed but not linked: 3
- Ni, 1988, Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research [article in Chinese]., Zhong Xi Yi Jie He Za Zhi, 8, 711
- Xie, 2005, The clinical efficacy of berberine in treatment of type 2 diabetes mellitus [article in Chinese]., Chin J Clin Healthcare, 8, 402
- Wei, 2004, Clinical study on improvement of type 2 diabetes mellitus complicated with fatty liver treatment by berberine [article in Chinese], Zhong Xi Yi Jie He Ganbing Za Zhi, 14, 334
Cited by
Sorted by citations
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P. K., & Prakash, O. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01614 · Cited by 1,114
Zhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630
Zhang, X., Zhao, Y., Zhang, M., Pang, X., Xu, J., Kang, C., Li, M., Zhang, C., Zhang, Z., Zhang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042529 · Cited by 615
“0 g/day/person for 3 months is effective and safe in the treatment of type 2 diabetes and dyslipidemia [15].”
BackgroundMethodInfluentialSelf-citationBerberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465
“These ongoing or completed clinical trials are summarized in Supplementary Table 1 (in supplemental material) [23, 112, 325, 351-364].”
BackgroundMethodInfluentialLan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.09.049 · Cited by 458
Metadata
- Authors
- Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., Ren, G., & Ning, G.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Second Military Medical University (CN)
- Department of Endocrinology (J.Y., G.R.), Min-Hang Hospital, Shanghai 201100, People’s Republic of China
- Corresponding author
- Ning, Guang
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-07-01
- Volume
- 93
- Issue
- 7
- Pages
- 2559-2565
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1969395627
- Cited by
- 573
- References
- 23
- Citations by year
- 2026: 30 · 2025: 27 · 2024: 28 · 2023: 33 · 2022: 41 · 2021: 54 · 2020: 46 · 2019: 42 · 2018: 33 · 2017: 23 · 2016: 29 · 2015: 32 · 2014: 34 · 2013: 31 · 2012: 25
- FWCI
- 14.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- berberine, type 2 diabetes, dyslipidemia, glucose-lowering effect, insulin sensitivity, glucose disposal rate, hyperinsulinemic-euglycemic clamp, HbA1c, serum lipids, triglycerides, LDL cholesterol, total cholesterol, plant alkaloids, constipation, drug safety, antidiabetic therapy, lipid-lowering therapy
- MeSH terms
- Adult, Aged, Berberine, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
